Zydus Lifesciences Share Price
(ZYDUSLIFE)
Check the latest share price of Zydus Lifesciences, details on performance, fundamentals, analyst ratings, peer comparison, financials, company news, analysis, and shareholding pattern for informed investing decisions.
₹888.05
▲0.17%
as on 04:01PM, 29 Apr 2025
NSE
Zydus Lifesciences Performance
Get real-time share price information, day’s high and low, historical returns and market stats.
Day's Low
Day's High
₹877.05Day's Price Range₹894.8552 Week's Low
52 Week's High
₹79552-Week Price Range₹1,324.3
| Returns % | |
| 1 Month Return | -2.67 % |
| 3 Month Return | -11.78 % |
| 1 Year Return | -7.09 % |
| Market Stats | |
| Previous Close | ₹886.55 |
| Open | ₹887.00 |
| Volume | 10.28L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹87,426.64Cr |
Zydus Lifesciences Fundamentals & Key Indicators
Check the fundamental ratios and key indicators of the company like P/E, P/B, PEG, Dividend yield etc.
Market Cap
₹87,426.64 Cr
Return on Equity (ROE)
8.43
Return on capital employed (ROCE)
9.84
P/B Ratio
2.7
Dividend Yield
0.72
EPS (TTM)
44.65
Sector
Pharmaceuticals
How to invest in Zydus Lifesciences
Investing in Zydus Lifesciences is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Zydus Lifesciences or ZYDUSLIFE on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Zydus Lifesciences or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Zydus Lifesciences with just a few clicks!
Zydus Lifesciences Valuation
Track how the P/E of Zydus Lifesciences has moved over time to understand valuation trends.
Zydus Lifesciences in the last 5 years
Lowest (7.34x)
March 7, 2022
Today (23.29x)
December 15, 2023
Industry (58.33x)
December 15, 2023
Highest (32.55x)
June 12, 2020
Today’s Price to Earnings Ratio: 23.29x
Analysts Recommendation on Zydus Lifesciences
Get updated buy, sell, and hold recommendations by analysts on Zydus Lifesciences.
based on 31 analysts
53.12%
Buy
31.25%
Hold
15.62%
Sell
53.12% of analysts recommend a 'BUY' rating for Zydus Lifesciences. Average target of ₹651.42
Source: S&P Global Market Intelligence
Analysts Forecast on Zydus Lifesciences
Get share price movements and forecasts by analysts on Zydus Lifesciences.
Zydus Lifesciences price forecast by 31 analysts
Downside of
High
₹770
Target
₹651.42
Low
₹490
Zydus Lifesciences target price ₹651.42, a slight downside of -25.03% compared to current price of ₹888.05. According to 31 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Zydus Lifesciences revenue growth forecast
Expected growth rate Q1, FY2025:21.33%
Forecast
Actual
Including amortisation and stock based compensations
Zydus Lifesciences EPS growth forecast
EPS estimate Q1, FY2025:63.55%
Forecast
Actual
Source: S&P Global Market Intelligence
Zydus Lifesciences Financials
Get the annual and quarterly financial summary of Zydus Lifesciences, including revenue, profit, loss and more.
Zydus Lifesciences Index Inclusions
Zydus Lifesciences Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Zydus Lifesciences.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 74.98% | 0.00 | |
| Foreign Institutions | 3.42% | 0.00 | |
| Mutual Funds | 5.59% | 0.00 | |
| Retail Investors | 8% | 0.00 | |
| Others | 8% | 0.00 |
Zydus Lifesciences vs Peers
Compare market cap, revenue, PE, and other key metrics of Zydus Lifesciences with its industry peers.
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹87,426.64 Cr | 31.24% | 0.59 | NA | NA | |
| BUY | ₹63,424.92 Cr | 22.06% | 0.55 | NA | NA | |
| HOLD | ₹46,605.29 Cr | 17.26% | 0.55 | NA | NA | |
| BUY | ₹28,250.05 Cr | 30.32% | 0.64 | NA | NA | |
| HOLD | ₹16,637.10 Cr | 6.43% | 0.57 | NA | NA |
Zydus Lifesciences News & Key Events
Latest news and events at one place to help you take investing decisions in Zydus Lifesciences.
Zydus Lifesciences Gains After USFDA Approval - 28 Apr, 2025
Zydus Lifesciences Ltd shares increased by 3.3% following a successful USFDA inspection of its API facility, which resulted in six minor observations, none related to data integrity. The company also plans to acquire an 85.6% stake in Amplitude Surgical SA.Zydus Lifesciences Faces Growth Challenges and FDA Observations - 26 Apr, 2025
Zydus Lifesciences reported strong revenue growth in 9MFY25 but faces headwinds and regulatory challenges, including six observations from the USFDA at its Gujarat API unit.Zydus MedTech Partners for TAVI Technology Commercialization - 21 Apr, 2025
Zydus Lifesciences' subsidiary, Zydus MedTech, has entered a strategic partnership with Braile Biomedica to exclusively commercialize Transcatheter Aortic Valve Implantation technology in India, Europe, and other markets.Zydus Lifesciences Navigates Patent Ruling and Expands Portfolio - 17 Apr, 2025
Zydus Lifesciences faces a US court ruling on Myrbetriq patents but continues sales. The company also moves to acquire Amplitude Surgical shares and enters a TAVI licensing agreement, indicating growth potential despite challenges.Zydus Shares Plunge After Patent Case Loss - 16 Apr, 2025
Zydus Lifesciences shares dropped significantly after a US Federal Court ruled against them in a patent case involving Myrbetriq, potentially requiring market withdrawal and leading to financial penalties. The ruling is seen as a major setback for Zydus's US market ambitions.Zydus Lifesciences Gains FDA Approval and Acquires Amplitude - 15 Apr, 2025
Zydus Lifesciences announced the acquisition of 85.6% of Amplitude Surgical for Euro 256.8 million and received FDA approval for Jaythari tablets, boosting investor confidence and share price.Zydus Pharmaceuticals Issues Recall for Chlorpromazine Tablets - 13 Apr, 2025
Zydus Pharmaceuticals (USA) Inc is recalling 3,144 bottles of chlorproMAZINE Hydrochloride Tablets due to CGMP deviations and impurity concerns. The Class II recall was initiated on April 3, 2025.Zydus Secures USFDA Approval for Deflazacort Tablets - 12 Apr, 2025
Zydus Lifesciences has received USFDA approval for Jaythari (Deflazacort) tablets, a treatment for Duchenne muscular dystrophy. The company also reported a significant profit increase in Q3 FY25.Zydus Gains USFDA Approval and Expands in France - 11 Apr, 2025
Zydus Lifesciences received USFDA approval for Jaythari (Deflazacort) Tablets, enhancing its U.S. market presence. Additionally, it established a subsidiary in France to acquire Amplitude Surgical, marking a strategic expansion into orthopedics.Zydus Lifesciences Announces Rs 750 Crore Share Buyback - 10 Apr, 2025
Zydus Lifesciences has announced a Rs 750 crore share buyback offer, set to commence on June 23 and close on July 6, 2025. The buyback will involve over 1.15 crore shares, representing approximately 1.13% of the company's total paid-up equity share capital.Zydus Lifesciences Faces Stock Decline Amid News - 05 Apr, 2025
On April 5, 2025, Zydus Lifesciences' subsidiary Sentynl Therapeutics published clinical studies on NULIBRY. However, shares of Zydus and peers fell 3-6% during trading.Zydus Lifesciences Shares Plunge Amid Tariff Concerns - 04 Apr, 2025
Zydus Lifesciences shares fell nearly 7% following U.S. President Trump's comments on potential pharmaceutical tariffs, raising concerns over profitability and market dependence. Analysts warn of limited ability to pass on costs, increasing vulnerability to trade barriers.Zydus Lifesciences Shares Surge on Tariff Exemption - 03 Apr, 2025
Zydus Lifesciences shares rose 5.25% to ₹937.95 after the U.S. exempted pharmaceuticals from a 26% tariff on Indian goods, boosting investor confidence. Brokerages remain cautiously optimistic about the company's U.S. revenue potential, emphasizing the importance of tariff exemptions for maintaining margins.
Insights on Zydus Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 6.32% to 6.36% in Mar 2025 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, ZYDUSLIFE has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Promoter Holding Up
Promoters have increased holdings from 74.98% to 74.99% in Mar 2025 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 5.30K Cr → 5.32K Cr (in ₹), with an average increase of 0.4% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 911.2 Cr → 1.02K Cr (in ₹), with an average increase of 11.0% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, ZYDUSLIFE stock has moved up by 4.0%
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 51.1% return, outperforming this stock by 59.0%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 6.84% to 6.68% in Mar 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 7.53% to 7.32% in Mar 2025 quarter
About Zydus Lifesciences
The company has a strong presence in the global market and is known for its high-quality pharmaceutical products. It manufactures a wide range of generic and specialty drugs, including cardiovascular, anti-infective, anti-diabetic, and oncology medicines. Zydus also produces over-the-counter products and nutritional supplements. Some of its top products include Zetia, Atorvastatin, and Metformin.
Zydus Lifesciences Ltd is also known for its popular brands, such as Cadila, Nutralite, and Zydus Wellness. The company has a strong presence in the Indian market, with its products being sold in more than 20,000 stores across the country. It also exports its products to over 100 countries worldwide.
Revenue: ₹6,046.50Cr as on June 2024 (Q2 24)
Net Profit: ₹1,463.60Cr as on June 2024 (Q2 24)
Listing date: 18 Apr, 2000
Chairperson Name: Pankaj R Patel
| Organisation | Zydus Lifesciences |
| Headquarters | Ahmedabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Indian Mutual Funds that own Zydus Lifesciences
Check out the Mutual Funds with significant holdings in Zydus Lifesciences.
Futures and Options
View the latest movement in Zydus Lifesciences Futures & Options, including strike prices, expiry dates, and percentage changes.
FAQs
What is Zydus Lifesciences Ltd price today?
Zydus Lifesciences Ltd share price today stands at ₹888.05, Open: ₹887, Previous Close: ₹886.55, High: ₹894.85, Low: ₹877.05, 52 Week High: ₹1324.3, 52 Week Low: ₹795.
How to Buy Zydus Lifesciences Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Zydus Lifesciences Ltd shares
What are today's traded volumes of Zydus Lifesciences Ltd?
Today's traded volume of Zydus Lifesciences Ltd(ZYDUSLIFE) is 10.28L.
What is today's market capitalisation of Zydus Lifesciences Ltd?
Today's market capitalisation of Zydus Lifesciences Ltd(ZYDUSLIFE) is ₹87,426.64 Cr.
What is the 52 Week High and Low Range of Zydus Lifesciences Ltd?
How much percentage Zydus Lifesciences Ltd is down from its 52 Week High?
Zydus Lifesciences Ltd (ZYDUSLIFE) share price is ₹888.05. It is down -32.94% from its 52 Week High price of ₹1324.3
How much percentage Zydus Lifesciences Ltd is up from its 52 Week low?
Zydus Lifesciences Ltd (ZYDUSLIFE) share price is ₹888.05. It is up 11.70% from its 52 Week Low price of ₹795